Although the majority of studies on HER2-targeted therapies have focused on breast cancer, HER2 positivity has also been observed in various other cancers, such as those arising in the gastrointestinal tract, urinary bladder, salivary glands, lung, ovaries, colon, and pancreas [3, 4]. The gene discussed is ERBB2; the disease is breast carcinoma.